Exploring Innovative Immunological Solutions for Biology
Dr. Shairaz baksh
Founder and President
Picture by Claudine Lavoie Photography
BioImmuno Designs, Inc. was created by Dr. Shairaz Baksh, a former Associate Professor at the University of Alberta in Edmonton, AB, Canada. We are a company dedicated to exploring the therapeutic potential of small molecules directed against inflammatory activators.
BioImmuno Designs, Inc. was created by Dr. Shairaz Baksh, a former Associate Professor at the University of Alberta in Edmonton, AB, Canada. We are a company dedicated to exploring the therapeutic potential of small molecules directed against inflammatory activators.
|
MISSION
To develop diagnostic tools for immunological disorders
To optimize the potential of small molecule therapeutics against hyperactive elements in the NFκB signaling family To uncover commonalities in inflammation driven diseases |
VISION
Our vision is to develop therapeutic approaches for diseases that have high unmet clinical need in addressable populations
Our primary focus is inflammatory drivers of inflammatory bowel disease (IBD) comprising Crohn's Disease (CD) and ulcerative colitis (UC) among other less prominent sub-types In addition, we have evidence that inflammation driven cancers (pancreatic cancer, Hodgkin’s Lymphoma, inflammatory breast cancer) and other inflammatory diseases (such as sarcoidosis, pancreatitis, multiple sclerosis, cystic fibrosis) may also be driven by NFκB modulators that are promoting IBD The development of a therapeutic drug targeting the common driver of inflammation in the above diseases would offer robust alternatives and/or offer combination therapy options |
APPROACH
Focus on inflammation and metabolic pathways driving inflammatory diseases
Use molecular modeling (docking) and chemoinformatics analyses to identify small molecule inhibitors to these common drivers Optimize small molecule potential by identifying analogs and derivatives with greater efficacy than the parent molecule Pre-clinical animal testing analyses to explore resolving inflammation in the major tissues (such as the colon, lung, pancreas and brain) Track ability to inhibit NFκB in vitro/in vivo and reverse the secondary (and tertiary) effects of acute and chronic inflammation |
